Abstract
OBJECTIVE: Large acute ST-elevation myocardial infarction (STEMI) sometimes leaves extensive ischemic damage despite timely and successful primary angioplasty. This clinical picture of good recanalization with incomplete reperfusion represents a good model to assess the reparative potential of locally administered cell therapy. Thus, we conducted a randomized controlled trial aimed at evaluating the effect of intracoronary administration of CD133 stem cells on myocardial blood flow and function in this setting. METHODS: Fifteen patients with large anterior STEMI, myocardial blush grade 0-1 and more than 50% ST-elevation recovery after optimal coronary recanalization (TIMI 3 flow) with stenting were randomly assigned to receive CD133 cells from either bone marrow (group A) or peripheral blood (group B), or to stay on drug therapy alone (group C). The cells were intracoronary injected within 10-14 days of STEMI. Infarct-related myocardial blood flow (MBF) was evaluated by NH positron emission tomography 2-5 days before cell administration and after 1 year. RESULTS: MBF increased in the infarct area from 0.419 (0.390-0.623) to 0.544 (0.371-0.729) ml/min per g in group A, decreased from 0.547 (0.505-0.683) to 0.295 (0.237-0.472) ml/min per g in group B and only slightly changed from 0.554 (0.413-0.662) to 0.491 (0.453-0.717) ml/min per g in group C (A vs. C: P = 0.023; B vs. C: P = 0.066). Left ventricular volume tended to increase more in groups B and C than in group A, ejection fraction and wall motion score index remained stable in the three groups. CONCLUSION: These findings support the hypothesis that intracoronary administration of bone marrow-derived, but not peripheral blood-derived CD133 cells 10-14 days after STEMI may improve long-term perfusion.
| Original language | English |
|---|---|
| Pages (from-to) | 239-248 |
| Number of pages | 10 |
| Journal | Journal of Cardiovascular Medicine |
| Volume | 12 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2011 |
Fingerprint
Keywords
- myocardial infarction
- PET
- stem cells
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Myocardial blood flow and infarct size after CD133+ cell injection in large myocardial infarction with good recanalization and poor reperfusion : Results from a randomized controlled trial. / Colombo, Alessandro; Castellani, Massimo; Piccaluga, Emanuela; Pusineri, Enrico; Palatresi, Simone; Longari, Virgilio; Canzi, Cristina; Sacchi, Elisabetta; Rossi, Edoardo; Rech, Roberto; Gerundini, Paolo; Viecca, Maurizio; Deliliers, Giorgio Lambertenghi; Rebulla, Paolo; Soligo, Davide; Giordano, Rosaria.
In: Journal of Cardiovascular Medicine, Vol. 12, No. 4, 04.2011, p. 239-248.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Myocardial blood flow and infarct size after CD133+ cell injection in large myocardial infarction with good recanalization and poor reperfusion
T2 - Results from a randomized controlled trial
AU - Colombo, Alessandro
AU - Castellani, Massimo
AU - Piccaluga, Emanuela
AU - Pusineri, Enrico
AU - Palatresi, Simone
AU - Longari, Virgilio
AU - Canzi, Cristina
AU - Sacchi, Elisabetta
AU - Rossi, Edoardo
AU - Rech, Roberto
AU - Gerundini, Paolo
AU - Viecca, Maurizio
AU - Deliliers, Giorgio Lambertenghi
AU - Rebulla, Paolo
AU - Soligo, Davide
AU - Giordano, Rosaria
PY - 2011/4
Y1 - 2011/4
N2 - OBJECTIVE: Large acute ST-elevation myocardial infarction (STEMI) sometimes leaves extensive ischemic damage despite timely and successful primary angioplasty. This clinical picture of good recanalization with incomplete reperfusion represents a good model to assess the reparative potential of locally administered cell therapy. Thus, we conducted a randomized controlled trial aimed at evaluating the effect of intracoronary administration of CD133 stem cells on myocardial blood flow and function in this setting. METHODS: Fifteen patients with large anterior STEMI, myocardial blush grade 0-1 and more than 50% ST-elevation recovery after optimal coronary recanalization (TIMI 3 flow) with stenting were randomly assigned to receive CD133 cells from either bone marrow (group A) or peripheral blood (group B), or to stay on drug therapy alone (group C). The cells were intracoronary injected within 10-14 days of STEMI. Infarct-related myocardial blood flow (MBF) was evaluated by NH positron emission tomography 2-5 days before cell administration and after 1 year. RESULTS: MBF increased in the infarct area from 0.419 (0.390-0.623) to 0.544 (0.371-0.729) ml/min per g in group A, decreased from 0.547 (0.505-0.683) to 0.295 (0.237-0.472) ml/min per g in group B and only slightly changed from 0.554 (0.413-0.662) to 0.491 (0.453-0.717) ml/min per g in group C (A vs. C: P = 0.023; B vs. C: P = 0.066). Left ventricular volume tended to increase more in groups B and C than in group A, ejection fraction and wall motion score index remained stable in the three groups. CONCLUSION: These findings support the hypothesis that intracoronary administration of bone marrow-derived, but not peripheral blood-derived CD133 cells 10-14 days after STEMI may improve long-term perfusion.
AB - OBJECTIVE: Large acute ST-elevation myocardial infarction (STEMI) sometimes leaves extensive ischemic damage despite timely and successful primary angioplasty. This clinical picture of good recanalization with incomplete reperfusion represents a good model to assess the reparative potential of locally administered cell therapy. Thus, we conducted a randomized controlled trial aimed at evaluating the effect of intracoronary administration of CD133 stem cells on myocardial blood flow and function in this setting. METHODS: Fifteen patients with large anterior STEMI, myocardial blush grade 0-1 and more than 50% ST-elevation recovery after optimal coronary recanalization (TIMI 3 flow) with stenting were randomly assigned to receive CD133 cells from either bone marrow (group A) or peripheral blood (group B), or to stay on drug therapy alone (group C). The cells were intracoronary injected within 10-14 days of STEMI. Infarct-related myocardial blood flow (MBF) was evaluated by NH positron emission tomography 2-5 days before cell administration and after 1 year. RESULTS: MBF increased in the infarct area from 0.419 (0.390-0.623) to 0.544 (0.371-0.729) ml/min per g in group A, decreased from 0.547 (0.505-0.683) to 0.295 (0.237-0.472) ml/min per g in group B and only slightly changed from 0.554 (0.413-0.662) to 0.491 (0.453-0.717) ml/min per g in group C (A vs. C: P = 0.023; B vs. C: P = 0.066). Left ventricular volume tended to increase more in groups B and C than in group A, ejection fraction and wall motion score index remained stable in the three groups. CONCLUSION: These findings support the hypothesis that intracoronary administration of bone marrow-derived, but not peripheral blood-derived CD133 cells 10-14 days after STEMI may improve long-term perfusion.
KW - myocardial infarction
KW - PET
KW - stem cells
UR - http://www.scopus.com/inward/record.url?scp=79953655063&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953655063&partnerID=8YFLogxK
U2 - 10.2459/JCM.0b013e328343d708
DO - 10.2459/JCM.0b013e328343d708
M3 - Article
C2 - 21372740
AN - SCOPUS:79953655063
VL - 12
SP - 239
EP - 248
JO - Journal of Cardiovascular Medicine
JF - Journal of Cardiovascular Medicine
SN - 1558-2027
IS - 4
ER -